🔎 Trials Near Me

Utama › Kanser Kolorektal › Oklahoma

Kajian klinikal Kanser Kolorektal di Oklahoma

22 kajian untuk Kanser Kolorektal sedang mencari peserta di lokasi di Oklahoma.

Bandar di Oklahoma

Teks kajian rasmi (Bahasa Inggeris)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • University of Oklahoma, Oklahoma City
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04585750

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Hospital Oklahoma City, Oklahoma City
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

Family Communications After Genetic Testing

  • Mercy Hospital Oklahoma City, Oklahoma City
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07143487

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

  • University of Oklahoma Health Sciences Center, Oklahoma City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT05803382

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

  • University of Oklahoma Health Sciences Center, Oklahoma City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06102902

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • University of Oklahoma, Oklahoma City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06128551

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

  • Stephenson Cancer Center, Oklahoma City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06445062

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

  • University of Oklahoma Health Sciences Center, Oklahoma City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06696768

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

  • Clinical Study Site, Oklahoma City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07228832

The Vanguard Study: Testing a New Way to Screen for Cancer

  • University of Oklahoma Health Sciences Center, Oklahoma City
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 45 hingga 75 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06995898

A Study of DM002 in Patients With Advanced Solid Tumors

  • University of Oklahoma Health Sciences Center, Oklahoma City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT06751329

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

  • University of Oklahoma Health Sciences Center, Oklahoma City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT05691491

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Stephenson Cancer Center, Oklahoma City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jul 2026 · NCT04657068

Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma

  • TSET Health Promotion Research Center, Oklahoma City
Mengambil peserta
Umur 45 hingga 75 · Semua jantina · Dikemas kini 30 Jul 2026 · NCT07254910

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

  • SSM OKC Hightower Clinical, Oklahoma City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jul 2026 · NCT03526835

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

  • Hightower Clinical, Oklahoma City
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT06937177

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

  • Mercy Hospital - OKC, Oklahoma City
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT07327489

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

  • OU Stephenson Cancer Center, Oklahoma City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jun 2026 · NCT06026410

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

  • OU Health Stephenson Cancer Center, Oklahoma City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Apr 2026 · NCT06720987

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

  • Mercy Hospital Oklahoma City, Oklahoma City
Mengambil pesertaFasa 3Sukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Mac 2026 · NCT07018869

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Mercy Hospital Oklahoma City, Oklahoma City
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06418204

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

  • Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2025 · NCT05234177

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.